Somatostatin for injection

Somatostatin is a synthetic cyclic fourteen amino acid peptide, which is completely identical to natural somatostatin in chemical structure and mechanism of action. Physiological somatostatin is mainly present in the hypothalamus and gastrointestinal tract. Somatostatin can inhibit the secretion of growth hormone, thyroid stimulating hormone, insulin and glucagon, and inhibit the secretion of gastric acid through intravenous injection. It also affects the absorption, motility, visceral blood flow and nutritional function of the gastrointestinal tract. Somatostatin can inhibit the secretion of gastrin, gastric acid and pepsin, thereby treating upper gastrointestinal bleeding, and can significantly reduce the blood flow of visceral organs without causing significant changes in systemic arterial blood pressure. Therefore, it has certain clinical value in the treatment of esophageal varicose bleeding. Somatostatin can reduce the endocrine and exocrine secretion of the pancreas, and is used to prevent and treat complications after pancreatic surgery. Somatostatin can also inhibit the secretion of glucagon, thereby effectively treating diabetic ketoacidosis.

The main ingredient of this product and its chemical name are: somatostatin acetate.

This product is white loose mass or powder.

Severe acute esophageal varicose bleeding. Severe acute gastric or duodenal ulcer bleeding, or complicated by acute erosive gastritis or hemorrhagic gastritis. Adjuvant treatment of pancreatic, biliary and intestinal fistulas. Prevention and treatment of complications after pancreatic surgery. Adjuvant treatment of diabetic ketoacidosis.

The lyophilized powder must be dissolved in saline before use. Stamista is administered intravenously, either by slow bolus injection (3 to 5 minutes) of 250 micrograms or by continuous drip at a rate of 250 micrograms per hour (equivalent to approximately 3.5 micrograms per kilogram of body weight per hour). For continuous drip administration, a 3 mg vial of Stamista is used to prepare a 12-hour supply of solution, the solvent of which can be either saline or 5% glucose solution. The infusion volume should be adjusted to 250 micrograms per hour, and an infusion syringe is recommended. For the treatment of severe acute upper gastrointestinal bleeding (including esophageal variceal bleeding): It is recommended to first slowly inject 250 micrograms of Stamista as a loading dose, followed immediately by an intravenous drip of 250 micrograms per hour. When the interval between two infusions is greater than 3 to 5 minutes, 250 micrograms of Stamista should be reinjected intravenously to ensure continuity of administration. When the bleeding is stopped (usually within 12 to 24 hours), treatment should be continued for 48 to 72 hours to prevent recurrence. For the above cases, the usual treatment duration is 120 hours. For adjunctive treatment of pancreatic fistula, biliary fistula, and intestinal fistula: Continuous intravenous drip at a rate of 250 micrograms per hour should be used until the fistula is closed (2 to 20 days). This treatment can be used as an adjunct to total parenteral nutrition. When the fistula is closed, intravenous drip of silamin should be continued for 1 to 3 days, and then gradually discontinued to prevent rebound effect. Prevention and treatment of complications after pancreatic surgery: At the beginning of the operation, as an adjunctive treatment, silamin is dripped at a rate of 250 micrograms per hour; after the operation, the drip is continued for 5 days. Adjunctive treatment of diabetic ketoacidosis: For patients with ketoacidosis, intravenous drip of silamin at a rate of 100 to 500 micrograms per hour combined with insulin treatment can relieve ketoacidosis within 3 hours and restore blood sugar to normal within 4 hours.

A few cases experienced nausea, dizziness, blushing, etc. When the infusion rate of silamin was higher than 50 micrograms per minute, the patient would experience nausea and vomiting.

Patients with confirmed allergies to silafenamide should not use this drug. Pregnant women should avoid using this product unless there is no other safe alternative.

Precautions during pregnancy and lactation: Avoid using this product by pregnant women unless there are no other safe alternatives.

This product can prolong the sleep time caused by cyclohexene barbiturate and intensify the effect of pentylene tetrazole, so it should not be used simultaneously with such drugs or drugs with the same effect. Since the interaction between somatostatin and other drugs has not been established, it is recommended that it should be administered alone.

This product should be stored in a dark and dry place below 25°C.

3mg

Changzhou Siyao Pharmaceuticals Co., Ltd.

• Founded in:

  1996-03-25

• Address:

  Meilongba, southern suburb of Changzhou, Jiangsu Province

• Tax NO.:

  91320400608126461P

• Registered Funds:

  $7.08 million

• Website:

  Log in to view

• Email:

  Log in to view